Search research articles
Contact Us
Filters
Showing results (1161-1170 of 1,180) with videos related to
Page
of 118
Sort By:
The British Journal of General Practice : the Journal of the Royal College of General Practitioners
|
January 16, 2024
Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trial
May Ee Png, Victoria Harris, Jenna Grabey, et al.
BMJ Open
|
July 14, 2018
Antivirals for influenza-Like Illness? A randomised Controlled trial of Clinical and Cost effectiveness in primary CarE (ALIC<sup>4</sup> E): the ALIC<sup>4</sup> E protocol
Emily Bongard, Alike W van der Velden, Johanna Cook, et al.
Genome Research
|
August 1, 1997
Multiplex sequencing of 1.5 Mb of the Mycobacterium leprae genome
D R Smith, P Richterich, M Rubenfield, et al.
The Lancet. Public Health
|
April 29, 2023
Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform
Linda Nab, Edward P K Parker, Colm D Andrews, et al.
The Journal of Comparative Neurology
|
January 3, 2023
Neurodegeneration in a novel invertebrate model system: Failed microtubule-mediated cell adhesion and unraveling of macroglia
Ruth Fabian-Fine, Anna M Aiken, Julia R Aug, et al.
Lancet (London, England)
|
December 17, 2019
Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial
Christopher C Butler, Alike W van der Velden, Emily Bongard, et al.
The Lancet. Infectious Diseases
|
September 12, 2024
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial
Victoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, et al.
Emerging Infectious Diseases
|
October 25, 2002
Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings
Daniel B Jernigan, Pratima L Raghunathan, Beth P Bell, et al.
Pharmacoepidemiology and Drug Safety
|
May 24, 2024
OpenSAFELY: A platform for analysing electronic health records designed for reproducible research
Linda Nab, Andrea L Schaffer, William Hulme, et al.
The New England Journal of Medicine
|
April 22, 2026
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients
Christopher C Butler, Andrew D Pinto, Victoria Harris, et al.
Page
of 118
Search research articles
Search
Showing results (1161-1170 of 1,180) with videos related to
Sort By:
Page
of 118
The British Journal of General Practice : the Journal of the Royal College of General Practitioners
|
January 16, 2024
Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trial
May Ee Png, Victoria Harris, Jenna Grabey, et al.
BMJ Open
|
July 14, 2018
Antivirals for influenza-Like Illness? A randomised Controlled trial of Clinical and Cost effectiveness in primary CarE (ALIC<sup>4</sup> E): the ALIC<sup>4</sup> E protocol
Emily Bongard, Alike W van der Velden, Johanna Cook, et al.
Genome Research
|
August 1, 1997
Multiplex sequencing of 1.5 Mb of the Mycobacterium leprae genome
D R Smith, P Richterich, M Rubenfield, et al.
The Lancet. Public Health
|
April 29, 2023
Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform
Linda Nab, Edward P K Parker, Colm D Andrews, et al.
The Journal of Comparative Neurology
|
January 3, 2023
Neurodegeneration in a novel invertebrate model system: Failed microtubule-mediated cell adhesion and unraveling of macroglia
Ruth Fabian-Fine, Anna M Aiken, Julia R Aug, et al.
Lancet (London, England)
|
December 17, 2019
Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial
Christopher C Butler, Alike W van der Velden, Emily Bongard, et al.
The Lancet. Infectious Diseases
|
September 12, 2024
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial
Victoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, et al.
Emerging Infectious Diseases
|
October 25, 2002
Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings
Daniel B Jernigan, Pratima L Raghunathan, Beth P Bell, et al.
Pharmacoepidemiology and Drug Safety
|
May 24, 2024
OpenSAFELY: A platform for analysing electronic health records designed for reproducible research
Linda Nab, Andrea L Schaffer, William Hulme, et al.
The New England Journal of Medicine
|
April 22, 2026
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients
Christopher C Butler, Andrew D Pinto, Victoria Harris, et al.
Page
of 118